[1] "PREDICTED PROBABILITIES TO RELAPSE IN TWO YEARS"
[1] "LASSO model"
                   Average predicted relapse % Low-isk patients' (<30%) predicted relapse %
Dymethyl fumarate                           62                                           18
Glatiramer acetate                          64                                           23
Natalizumab                                 54                                           20
                   High-isk patients' (>50%) predicted relapse %
Dymethyl fumarate                                             93
Glatiramer acetate                                            93
Natalizumab                                                   83
[1] "Pre-Specified model"
                   Average predicted relapse % Low-isk patients' (<30%) predicted relapse %
Dymethyl fumarate                           53                                           20
Glatiramer acetate                          56                                           23
Natalizumab                                 46                                           23
                   High-isk patients' (>50%) predicted relapse %
Dymethyl fumarate                                             84
Glatiramer acetate                                            86
Natalizumab                                                   69
[1] "ORs OF RELAPSING IN TWO YEARS"
[1] "LASSO model"
                   Average OR Low-isk patients' (<30%) OR High-isk patients' (>50%) OR 
Dymethyl fumarate        0.52                        0.25                          0.81
Glatiramer acetate       0.57                        0.35                          0.81
Natalizumab              0.29                        0.29                          0.28
[1] "Pre-Specified model"
                   Average OR Low-isk patients' (<30%) OR High-isk patients' (>50%) OR 
Dymethyl fumarate        0.42                        0.31                          0.53
Glatiramer acetate       0.50                        0.38                          0.63
Natalizumab              0.31                        0.40                          0.23
